DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Werner syndrome — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleWerner syndrome maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for werner syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein tyrosine phosphatase non-receptor type 11 (PTPN11) — PTPN11 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pgedrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4GWF · 2.1 Å · ligand TRIETHYLENE GLYCOL (PGE). Experimental structure, not a prediction.
What the evidence adds up to
Approximately 75% of all Werner syndrome patients recognised between 1904 and 2008 worldwide are of Japanese origin, and most case reports and clinical studies have been published in Japanese journals. In Japan, recent longevity and delayed age-associated manifestations have been observed both in WS patients and in the general population, suggesting a common environmental effect on some gene other than WRN. Werner syndrome is an inherited disorder that produces somatic stunting, premature ageing, and early onset of degenerative and neoplastic diseases. Cultured fibroblasts from WS subjects undergo premature replicative senescence and provide a cellular model for the disorder.
A 1993 hypothesis proposed that the primary defect in WS is a mutation in a gene for a trans-acting repressor protein, reducing its binding affinity for shared regulatory regions of several genes including those that encode inhibitors of DNA synthesis (IDS). The mutant repressor was thought to trigger premature expression of IDS and other genes, inhibiting DNA synthesis and causing early cellular senescence. Several overexpressed gene sequences isolated from a WS fibroblast cDNA library were shown to possess the capacity to inhibit DNA synthesis and disrupt many normal biochemical processes. A similar constellation of genes is overexpressed in WS and in senescent normal fibroblasts, suggesting a common molecular genetic pathway for replicative senescence.
By 1999, WS was classified as one of a group of human genetic diseases linked to deficits in cellular helicase function. The spectrum of WRN mutations, the organisation and potential functions of the WRN protein, and potential mechanistic links between loss of WRN function and the pathogenesis of WS clinical and cellular phenotypes were reviewed. No specific drug intervention is described in any of these abstracts.
What is still missing is any clinical trial of a drug for Werner syndrome, any patient stratification by mutation type, and any funding for translational research that moves beyond cellular and genetic hypothesis into human testing.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
BioScience Trends · 2013 · 94 citations · open access
Werner syndrome: A changing pattern of clinical manifestations in Japan (1917-2008)
AbstractAs ~75% of the Werner syndrome (WS) patients recognized between 1904 and 2008 all over the world are of Japanese origin, the most case reports and clinical studies on WS has been published in Japanese journals. Thus, the detailed English-written clinical review on the recent WS case reports has been warranted. Although WS has been characterized by a variety of clinical manifestations mimicking premature aging, the recent longevity and delayed age-associated manifestations observed both from Japanese WS and general population may suggest a common environmental effect on some gene(s) other than WRN and may give us a newer pathophysiological look at WS and also natural aging through the molecular dysfunction of WRN.
AbstractWerner syndrome (WS) is one of a group of human genetic diseases that have recently been linked to deficits in cellular helicase function. We review the spectrum of WS-associated WRN mutations, the organization and potential functions of the WRN protein, and potential mechanistic links between the loss of WRN function and pathogenesis of the WS clinical and cellular phenotypes.
Hypothesis: Werner syndrome and biological ageing: A molecular genetic hypothesis
AbstractWerner syndrome (WS) is an inherited disorder that produces somatic stunting, premature ageing and early onset of degenerative and neoplastic diseases. Cultured fibroblasts derived from subjects with WS are found to undergo premature replicative senescence and thus provide a cellular model system to study the disorder. Recently, several overexpressed gene sequences isolated from a WS fibroblast cDNA library have been shown to possess the capacity to inhibit DNA synthesis and disrupt many normal biochemical processes. Because a similar constellation of genes is overexpressed in WS and senescent normal fibroblasts, these data suggest the existence of a common molecular genetic pathway for replicative senescence in both types of cell. We propose that the primary defect in WS is a mutation in a gene for a trans-acting repressor protein that reduces its binding affinity for shared regulatory regions of several genes, including those that encode inhibitors of DNA synthesis (IDS). The mutant WS repressor triggers a sequence of premature expression of IDS and other genes, with resulting inhibition of DNA synthesis and early cellular senescence, events which occur much later in normal cells.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
